Bio-Technopark

In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video

read more

Leasing

In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.

read more

Services

The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.

 

read more

News

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

Cologne, Germany, November 19, 2026 – DISCO Pharmaceuticals (“DISCO”) today announced a strategic collaboration and option- to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need. Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is...

read more

GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic

NEWTON, Mass. and WÄDENSWIL, Switzerland, Nov. 16, 2026 /PRNewswire/ -- GlycoEra, a biotechnology company pioneering precision immunology through the selective removal of disease-driving proteins, today announced that it has initiated dosing of healthy subjects in a Phase 1a clinical trial of GE8820, the first IgG4-selective extracellular protein degrader to enter...

read more

Events

  • Bio-Technopark After Work Networking Aperitif
    01.12.2026